Open access · CC-BY
via OpenAlex
Insulin-like Growth Factor-1 (IGF-1) Related Drugs in Pain Management
Pharmaceuticals · 2023 · ▲ 5 citations
Abstract
Objective. The aim of this review is to explore the role of IGF-1 and IGF-1R inhibitors in pain-related conditions and assess the effectiveness of IGF-1-related drugs in pain management. Specifically, this paper investigates the potential involvement of IGF-1 in nociception, nerve regeneration, and the development of neuropathic pain. Methods. We conducted a search of the PUBMED/MEDLINE database, Scopus, and the Cochrane Library for all reports published in English on IGF-1 in pain management from origination through November 2022. The resulting 545 articles were screened, and 18 articles were found to be relevant after reading abstracts. After further examination of the full text of these articles, ten were included in the analysis and discussion. The levels of clinical evidence and implications for recommendations of all the included human studies were graded. Results. The search yielded 545 articles, of which 316 articles were deemed irrelevant by reading the titles. There were 18 articles deemed relevant after reading abstracts, of which 8 of the reports were excluded due to lack of IGF-1-related drug treatment after reviewing the full text of the articles. All ten articles were retrieved for analysis and discussion. We found that IGF-1 may have several positive effects on pain management, including promoting the resolution of hyperalgesia, preventing chemotherapy-induced neuropathy, reversing neuronal hyperactivity, and elevating the nociceptive threshold. On the other hand, IGF-1R inhibitors may alleviate pain in mice with injury of the sciatic nerve, bone cancer pain, and endometriosis-induced hyperalgesia. While one study showed marked improvement in thyroid-associated ophthalmopathy in humans treated with IGF-1R inhibitor, two other studies did not find any benefits from IGF-1 treatment. Conclusions. This review highlights the potential of IGF-1 and IGF-1R inhibitors in pain management, but further research is needed to fully understand their efficacy and potential side effects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/ph16050760
- Canonical
- link ↗
- Fetched
- 2026-10-22 MST
Cite this
APA
Jin, S., & Cheng, J. (2023). Insulin-like Growth Factor-1 (IGF-1) Related Drugs in Pain Management. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph16050760
Vancouver
Jin S, Cheng J. Insulin-like Growth Factor-1 (IGF-1) Related Drugs in Pain Management. Pharmaceuticals. 2023. doi:10.3390/ph16050760.
BibTeX
@article{seokhyun2023Insuli,
title = {Insulin-like Growth Factor-1 (IGF-1) Related Drugs in Pain Management},
author = {Seokhyun Jin and Jianguo Cheng},
journal = {Pharmaceuticals},
year = {2023},
doi = {10.3390/ph16050760},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Molecular Sciences 2023
Open access · CC-BY
Intermittent Fasting as a Potential Therapeutic Instrument for Major Depression Disorder: A Systematic Review of Clinical and Preclinical Studies
bioRxiv (Cold Spring Harbor Laboratory) 2019
Preprint · CC-BY
Comparative Transcriptomic Signature of the Simulated Microgravity Response in Caenorhabditis elegans
Current Diabetes Reviews 2025
Open access · CC-BY
Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review
Frontiers in Endocrinology 2022
Open access · CC-BY
Antidepressants as Endocrine Disrupting Compounds in Fish
Cureus 2023
Open access · CC-BY
Time-Restricted Feeding and Intermittent Fasting as Preventive Therapeutics: A Systematic Review of the Literature
Aging Cell 2008
Citation only